Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Spotlight on statins.

M S Weber1, O Stuve, O Neuhaus

  • 1Department of Neurology and Program in Immunology, University of California, San Francisco, 513 Parnassus Avenue, S-268, San Francisco, CA 94143-0435, USA.

International MS Journal
|November 22, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evidence for the Collective Nature of Radial Flow in Pb+Pb Collisions with the ATLAS Detector.

Physical review letters·2026
Same author

Evidence for the Dimuon Decay of the Higgs Boson in pp Collisions with the ATLAS Detector.

Physical review letters·2025
Same author

Evidence for Longitudinally Polarized W Bosons in the Electroweak Production of Same-Sign W Boson Pairs in Association with Two Jets in pp Collisions at sqrt[s]=13  TeV with the ATLAS Detector.

Physical review letters·2025
Same author

Observation of tt[over ¯] Production in Pb+Pb Collisions at sqrt[s_{NN}]=5.02  TeV with the ATLAS Detector.

Physical review letters·2025
Same author

Search for Dark Matter Produced in Association with a Dark Higgs Boson in the bb[over ¯] Final State Using pp Collisions at sqrt[s]=13  TeV with the ATLAS Detector.

Physical review letters·2025
Same author

Search for Magnetic Monopole Pair Production in Ultraperipheral Pb+Pb Collisions at sqrt[s_{NN}]=5.36  TeV with the ATLAS Detector at the LHC.

Physical review letters·2025
Same journal

American academy of neurology annual meeting.

International MS journal·2011
Same journal

Tumour Necrosis Factor Neutralization in MS: A Cautionary Tale.

International MS journal·2011
Same journal

The clinical usefulness of routine MRI assessment.

International MS journal·2011
Same journal

Acute Psychosis as the Initial Presentation of MS: A Case Report.

International MS journal·2011
Same journal

Russell Brains Review of MS.

International MS journal·2011
Same journal

Epstein-Barr Virus and MS:Causality or Association?

International MS journal·2011
See all related articles

Statins, commonly used for cardiovascular health, show promise for autoimmune disorders like multiple sclerosis (MS) by modulating immune function independently of cholesterol. These drugs may offer new therapeutic avenues for MS patients.

Area of Science:

  • Immunology
  • Neuroscience
  • Pharmacology

Background:

  • Statins are widely prescribed for cardiovascular disease prevention.
  • Emerging evidence suggests statins possess immunomodulatory properties beneficial for autoimmune disorders.
  • Their mechanism involves inhibiting protein prenylation, independent of lipid-lowering effects.

Purpose of the Study:

  • To investigate the therapeutic potential of statins in autoimmune diseases, specifically multiple sclerosis (MS).
  • To explore the immunomodulatory effects of statins in the context of neuroinflammation.

Main Methods:

  • Utilized experimental autoimmune encephalomyelitis (EAE), a mouse model for MS.
  • Administered statins to assess their impact on disease progression and paralysis.

Related Experiment Videos

  • Evaluated the synergistic effects of statins with existing MS therapies.

    • Main Results:

    • Statins demonstrated efficacy in preventing and reversing paralysis in the EAE mouse model.
    • Statins exhibited synergistic therapeutic benefits when combined with certain MS-approved agents.
    • The immunomodulatory effects were linked to the inhibition of protein prenylation.

    Conclusions:

    • Statins hold significant therapeutic potential for multiple sclerosis (MS) and other autoimmune conditions.
    • The findings support ongoing clinical trials evaluating statins as a novel MS therapy.
    • Targeting protein prenylation represents a promising strategy for autoimmune disease treatment.